Chungen Pan

Title: Chungen Pan: Innovator in Oncolytic Virus Research

Introduction

Chungen Pan is a prominent inventor based in Guangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative treatments for cancer. With a total of 7 patents, his work focuses on harnessing the power of recombinant oncolytic viruses and HIV fusion inhibitors.

Latest Patents

One of Chungen Pan's latest patents involves recombinant oncolytic viruses for the treatment of metastatic cancers. This patent discloses recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane (FAST) proteins. The oncolytic activity of these viruses can be utilized to treat primary and metastatic cancers, especially those originating from breast and colon cancers. Another notable patent is for stabilized trimeric HIV-1 GP41 fusion inhibitor polypeptides. This patent describes trimeric polypeptide pharmaceutical compositions that include monomers with specific amino acid sequences from the transmembrane glycoprotein of HIV, along with a trimerization motif.

Career Highlights

Chungen Pan has worked with several reputable organizations throughout his career. Notably, he has been associated with the New York Blood Center, Inc. and Entos Pharmaceuticals Inc. His work in these institutions has allowed him to advance his research and contribute to significant scientific discoveries.

Collaborations

Chungen Pan has collaborated with esteemed colleagues in his field, including Shibo Jiang and Zhi Qi. These collaborations have further enriched his research and innovation efforts.

Conclusion

Chungen Pan is a distinguished inventor whose work in oncolytic viruses and HIV fusion inhibitors has the potential to revolutionize cancer treatment. His innovative patents and collaborations highlight his commitment to advancing medical science.